World Conference on Lung Cancer Opens, Expected to Boost the Pharmaceutical Sector; Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) Posts Outstanding Constituent Performance
- AKESO announced on September 3 that the interim overall survival analysis of HARMONi-2 reached statistical significance, making it the world's first Phase III study in which a single agent achieved dual positivity on both PFS and OS in a head-to-head comparison against Keytruda; its share price once climbed to HKD 101.
- INNOVENT BIO's H-shares gained about 34% year to date, and GENSCRIPT BIO surged 15% intraday on September 17, driving the Chinaamc Hang Seng Hong Kong Biotech Index ETF up nearly 2% against the market trend.
- The Chinaamc Hang Seng Hong Kong Biotech Index ETF has declined about 12.4% over the past year; the Hang Seng Hong Kong-Listed Biotech Index it tracks comprises top Chinese biotech companies listed in Hong Kong, including pre-profit companies under Chapter 18A of the Listing Rules.
The Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) has declined about 12.4% over the past year. Its constituents strengthened amid divergence: AKESO announced on September 3 that the interim analysis of overall survival (OS) for HARMONi-2 reached statistical significance, making it the world's first Phase III study in which a single agent achieved dual positivity on both PFS and OS in a head-to-head comparison against Keytruda, with its share price once climbing to HKD 101; INNOVENT BIO's H-shares gained about 34% year to date; on September 17, GENSCRIPT BIO surged 15% intraday, driving the Chinaamc Hang Seng Hong Kong Biotech Index ETF up nearly 2% against the market trend.
At the World Conference on Lung Cancer held on September 12–15, Chinese innovative drugs set a record with 19 oral presentations and 45 mini oral presentations; the Phase III interim analysis of HANSOH PHARMA's B7-H3-targeted ADC risvutatug rezetecan met the primary OS endpoint, and AKESO's HARMONi-2 interim OS met the endpoint, directly driving the sector higher.
The ETF tracks the Hang Seng Hong Kong-Listed Biotech Index, compiled by Hang Seng Indexes Company Limited. Its constituents are top Chinese biotech companies listed in Hong Kong (including pre-profit companies under Chapter 18A of the Listing Rules): it provides one-stop exposure to globally competitive innovative drug leaders such as AKESO, INNOVENT BIO and BEONE MEDICINES, and includes pre-profit 18A biotechs, giving it greater elasticity at the R&D-to-commercialisation inflection point than comparable A-share indices.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) Rises 1.50% in Morning Trade, Turnover at HKD 34.9055 Million
- Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) Falls 0.90% in Morning Trade, Turnover at HKD 27.3021 Million
- ChinaAMC Hang Seng Hong Kong Biotech Index ETF (03069.HK) Rises 3.94%, Turnover Reaches HKD 69.2478 Million
- ChinaAMC Hang Seng Hong Kong Biotech Index ETF (03069.HK) Falls 1.57%, AUM Reaches HKD 2.572 Billion
- Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) Falls 0.82% in Morning Trade, Latest NAV at HKD 15.797
